• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Colgate Taps Verily’s Baseline Platform for Oral Health Research

by Jasmine Pennic 08/06/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Colgate Taps Verily’s Baseline Platform for Oral Health Research

What You Should Know:

– Verily and Colgate, today announce a new oral health study as part of Verily’s ongoing Baseline Health Study that will aim to improve understanding of the connections between oral health and overall human health. The study will assess how oral health practices affect health more broadly.

– The study’s goal is to see how oral health practices, including intensive non-surgical periodontal therapy, as well as a robust Colgate home oral hygiene regimen monitored through its hum smart toothbrush connected technologies, affect health more broadly. Periodontal treatment focuses on addressing issues with gums and oral health before they become more serious and potentially lead to tooth loss.

Study Enrollment Details

The study will enroll current participants in Verily’s ongoing Baseline Health Study, ages 18 and older,

with prediabetes, type 2 diabetes and/or cardiovascular disease for up to 18 months. The non-surgical

periodontal therapy will be administered by co-investigators at the University of North Carolina at

Chapel Hill Adams School of Dentistry. The “Baseline Oral Health Study: UNCoVer the Connections to

General Health” and has been posted to clinicaltrials.gov.

“We’ve known for some time that oral health, cardiovascular disease and diabetes were interrelated.

The depth of biological measurement in the Baseline Health Study combined with the dental expertise

of the UNC Adams School of Dentistry and Colgate will enable us to expand our knowledge base

dramatically,” said Rob Califf, MD, Head of Clinical Policy at Verily and Google Health.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Verily

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |